Healthy Vessel Seen in 6-Month Follow-up Exam on First Patient to Receive Preventive Treatment for Vulnerable Plaque
ROTTERDAM, Netherlands and DOYLESTOWN, Pa., Jan. 15 /PRNewswire/ -- The first patient receiving focal preventive treatment for vulnerable plaque recently underwent a 6-month follow-up examination that revealed successful stabilization of the target plaque. The interventional cardiology team led by Professor Patrick W. Serruys, MD, PhD, of Erasmus University, placed a vProtect(TM) Luminal Shield in the left anterior descending (LAD) coronary artery of the patient at Erasmus Medical Center in Rotterdam in June of 2008. The 64-year-old man is enrolled in SECRITT I, a pilot study designed to evaluate the vProtect(TM) Luminal Shield as a treatment for vulnerable plaques--"silent" atherosclerotic deposits in the coronary arteries that do not produce symptoms until they rupture with potentially fatal consequences.
To date, the treated artery demonstrated excellent blood flow and healing. As part of the healing process the Shield is now covered by a thin layer of tissue, incorporating it into the arterial wall. This is a hallmark of a successful implant and demonstrated that the Shield performed much better than would be expected for traditional bare metal stents and comparable to the first generation of drug-eluting stents.
"The self-expanding vProtect(TM) Luminal Shield minimizes injury on deployment enabling safe placement over rupture-prone vulnerable plaques," said Patricia Scheller, CEO of Prescient Medical, the manufacturer of the vProtect(TM) Luminal Shield. "Given that there are more than 500,000 sudden cardiac deaths in the US, and more than 300,000 in Europe each year, we are pleased that our device addresses untreated vulnerable plaques, the culprit in a majority of sudden cardiac deaths."
Patients enrolled in SECRITT I have been referred to the cath lab for
Page: 1 2 Related biology technology :1
|SOURCE Prescient Medical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces2
. Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA Superbug3
. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology4
. Blue Cross and Blue Shield of Texas Launches an Integrated Medical-Dental Health Program5
. Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers6
. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals7
. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device8
. SyntheMed Announces FDA Clearance of SinusShield(TM)9
. Biomatricas RNAstable(TM) Stabilizes RNA at Room Temperature10
. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease11
. Atrial Fibrillation Month - StopAfib.org Announces September Focus on Life-Threatening Irregular Heartbeat